Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 119.28 percent increase over losses of $(1.66) per share from the same period last year. The company reported quarterly sales of $288.770 million which missed the analyst consensus estimate of $318.050 million by 9.21 percent. This is a 172.00 percent increase over sales of $106.164 million the same period last year.